Generic Medicine Info
Indications and Dosage
Chronic heart failure
Adult: In stable chronic heart failure with reduced systolic left ventricular function as an adjunct to ACE inhibitors, diuretics, and optionally cardiac glycosides: Initially, 1.25 mg once daily for 1 week. If tolerated, increase gradually as follows: 2.5 mg once daily for a further week, 3.75 mg once daily for a further week, 5 mg once daily for the 4 following weeks, 7.5 mg once daily for the 4 following weeks, then 10 mg once daily for maintenance. Max: 10 mg once daily. Gradual dose reduction may be considered if the Max recommended dose is not well tolerated. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).

Angina pectoris, Hypertension
Adult: Initially, 5 mg once daily. Usual maintenance dose: 10 mg once daily. Max: 20 mg daily. Adjust dose according to individual requirements.
Special Patient Group
Patients with bronchospastic disease: Initially, 2.5 mg once daily.
Renal Impairment
Angina pectoris; Hypertension:
CrCl (mL/min) Dosage
<40 Initially, 2.5 mg once daily. Max: 10 mg once daily.
Hepatic Impairment
Angina pectoris; Hypertension:
Initially, 2.5 mg once daily. Max: 10 mg once daily.
May be taken with or without food.
Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy; symptomatic bradycardia; cardiogenic shock, 2nd- and 3rd-degree atrioventricular block (without pacemaker), sinoatrial block, severe bronchial asthma or COPD; sick sinus syndrome, symptomatic hypotension; severe peripheral arterial occlusive disease, severe Raynaud's syndrome; metabolic acidosis, untreated phaeochromocytoma.
Special Precautions
Patient with ischaemic heart disease, 1st-degree atrioventricular block, bronchospastic disease, diabetes mellitus with large fluctuations in blood glucose levels; peripheral arterial occlusive disease, Prinzmetal's angina, phaeochromocytoma, psoriasis or history of psoriasis; thyrotoxicosis, myasthenia gravis, history of anaphylactic reaction to allergens. Patients undergoing surgery involving general anaesthesia; ongoing desensitisation therapy or strict fasting. Avoid abrupt withdrawal. May mask the signs and symptoms of hypoglycaemia and hyperthyroidism (particularly tachycardia). Renal (CrCl <40 mL/min) and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Cardiac disorders: Bradycardia, worsening of pre-existing heart failure (in patients with chronic heart failure).
Gastrointestinal disorders: Nausea, vomiting, constipation, diarrhoea.
General disorders and administration site conditions: Fatigue, asthenia.
Nervous system disorders: Headache, dizziness.
Vascular disorders: Feeling of coldness or numbness in the extremities, hypotension.
Monitoring Parameters
Monitor blood pressure, heart rate, ECG; serum glucose (in diabetic patients); symptoms of bronchospasm (in patients with pre-existing bronchospastic disease) and worsening heart failure during the titration phase.
Symptoms: Bradycardia, bronchospasm, hypotension, acute cardiac insufficiency, hypoglycaemia. Management: Supportive and symptomatic treatment. The following may be administered to treat symptoms: IV atropine for bradycardia (isoprenaline or another agent with positive chronotropic properties may be given if the response is insufficient; transvenous pacemaker insertion may be considered if necessary); IV fluids and vasopressors for hypotension (IV glucagon may also be useful); isoprenaline for 2nd- or 3rd-degree atrioventricular block (may consider transvenous cardiac pacemaker insertion); IV diuretics, inotropic agents or vasodilating agents for acute worsening of heart failure; bronchodilator therapy (e.g. isoprenaline, β2-sympathomimetic drugs and/or aminophylline) for bronchospasm; IV glucose for hypoglycaemia.
Drug Interactions
Concomitant use with Ca antagonist (e.g. verapamil, diltiazem) may lead to reduced contractility of the heart muscle and delayed atrioventricular impulse conduction. Concomitant use of centrally acting antihypertensive drugs (e.g. clonidine, methyldopa, moxonidine, rilmenidine) may further decrease the central sympathetic tonus (reduction of heart rate and cardiac output, vasodilation). Effect on atrioventricular conduction time may be potentiated with Class I (e.g. disopyramide, quinidine) and Class III (e.g. amiodarone) antidysrhythmic agents. May increase atrioventricular conduction time and the risk of bradycardia with parasympathomimetic drugs. May intensify the blood sugar-lowering effects of insulin and oral antidiabetic agents. Reduced heart rate and increased atrioventricular conduction time with digitalis glycosides. May attenuate reflex tachycardia and increase the risk of hypotension with anaesthetic drugs. NSAIDs may reduce the hypotensive effect of bisoprolol. Concomitant use of β-sympathomimetic agents (e.g. isoprenaline, dobutamine) and bisoprolol may reduce the effect of both agents. May unmask the α-adrenoceptor-mediated vasoconstrictor effects of sympathomimetics that activate both β- and α-adrenoceptors (e.g. norepinephrine, epinephrine) leading to increased blood pressure and exacerbated intermittent claudication. Increase risks of hypotension with other antihypertensive agents (e.g. dihydropyridine Ca antagonists) and other drugs with blood pressure lowering potential (e.g. TCAs, barbiturates, phenothiazines). Increased risk of bradycardia with mefloquine. Enhanced hypotensive effect and risk for hypertensive crisis with MAOIs (except MAO-B inhibitors). Reduced elimination half-life with rifampicin. May produce an excessive reduction of sympathetic activity with catecholamine-depleting drugs (e.g. reserpine, guanethidine). Topical β-blockers (e.g. eye drops for glaucoma treatment) may add to the systemic effects of bisoprolol. Concurrent use with moxisylyte may cause severe postural hypotension.
Lab Interference
May cause a false-positive aldosterone/renin ratio.
Description: Bisoprolol is a potent and highly selective β1-adrenoreceptor blocking agent with little or no effect on β2-receptors of the bronchial and vascular smooth muscle except at high doses (≥20 mg). Its mechanism of action in the treatment of hypertension is not fully established but may be associated with reduction of cardiac output, inhibition of renin release by the kidneys, and diminution of sympathetic outflow from the vasomotor centres in the brain. In the treatment of angina, the blockade of β1-receptors reduces heart action thereby reducing oxygen demand.
Onset: 1-2 hours.
Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract. Bioavailability: Approx 90%. Time to peak plasma concentration: 2-4 hours.
Distribution: Widely distributed in the body with high concentrations in the heart, liver, lungs, and saliva. Crosses the blood-brain barrier. Volume of distribution: 3.5 L/kg. Plasma protein binding: Approx 30%.
Metabolism: Extensively metabolised in the liver to inactive metabolites; undergoes significant first-pass metabolism (approx 20%).
Excretion: Via urine (50% as unchanged drug; remainder as inactive metabolites); faeces (<2%). Elimination half-life: 9-12 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2405, Bisoprolol. Accessed June 28, 2022.

Store between 20-25°C. Protect from moisture.
MIMS Class
Anti-Anginal Drugs / Beta-Blockers
ATC Classification
C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Anon. Bisoprolol Fumarate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 17/05/2022.

Anon. Bisoprolol. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 17/05/2022.

Bisoprolol Fumarate 10 mg Tablets (Healthcare Pharma Limited). MHRA. Accessed 17/05/2022.

Bisoprolol Fumarate 5 mg Film-coated Tablets (Flamingo Pharma UK Ltd). MHRA. Accessed 17/05/2022.

Bisoprolol Fumarate Tablet, Film Coated (TruPharma, LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 17/05/2022.

Buckingham R (ed). Bisoprolol Fumarate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 17/05/2022.

Cardicor 1.25 mg Film-coated Tablets (Merck Serono Limited). MHRA. Accessed 17/05/2022.

Concor 10 mg Film Coated Tablet (Merck Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 21/06/2022.

Douglas Pharmaceuticals Ltd. Bosvate 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg Tablet data sheet 7 September 2018. Medsafe. Accessed 17/05/2022.

Joint Formulary Committee. Bisoprolol Fumarate. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 17/05/2022.

Vasoten F.C. Tablets 5 mg (Apex Pharmacy Marketing Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. Accessed 17/05/2022.

Disclaimer: This information is independently developed by MIMS based on Bisoprolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Corbis
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in